Kornimate/medical-research-clean huggingface dataset:
yoga in the treatment of osteoporosis

Conditions: Osteoporosis

Summary: the study measures change in bone mineral density by the dexa scan before and two or more years after beginning ten minutes of daily yoga designed to put pressure on the spine, hips and femur.

after collecting blood and urine samples, and pre-study dexa scans, qualifying patients are given an entry dexa scan and a dvd with instructions to advance from beginner versions of 12 iyengar-style yoga poses to more advanced levels in daily practice for 2 years. fter two years or more, subsequent dexa scans are recorded. interested participants are also encouraged to have hip and spine x-rays, and bone quality studies on study entry and two years later. actual subject participation, intercurrent illnesses, fractures and changes in medication are self-monitored with an on line scorecard, supplemented by emails and/or telephone calls when judged necessary by the pi. results are calculated by change in bone mineral density in the lumbar spine, hips and femurs by the dexa scan, changes in osteoarthritis according to the x-rays, and changes in bone quality before and two or more years after beginning the ten minutes of daily yoga. dose-response relationships between the amount and intensity of yoga practice and bone mineral density and quality are sought. yoga-related fractures and other adverse effects are also noted.

Eligibility criteria:
inclusion criteria: * past dexa scan and, all within 6 months of study entry, dexa scan and normal values for: metabolic panel, tsh, pth, esr (or crp), vitamin d 25 hydroxy, vitamin d 1,25 dihydroxy, urine ntx. exclusion criteria: * known metabolic bone disease such as osteogenesis imperfecta, current treatment with steroids, chemotherapy, or currently healing fractures of lumbar spine, hips or femurs.

Keywords: osteoporosis yoga
the crohn's therapy, resource, evaluation, and assessment tool registry

Conditions: Crohn's Disease

Summary: the purpose of this study is to evaluate the long-term clinical, economic and humanistic outcomes of various treatment regimens, including infliximab, in crohn's disease in real world medical practice.

the treat (the crohn's therapy, resource, evaluation, and assessment tool) registry is a prospective, observational, multicenter, long-term registry featuring clinical, economic, and humanistic measures characterizing the treatment of crohn's disease. the physicians will track treatments and patient outcomes over at least a 5-year period. physicians are expected to manage patients as they would under normal practice conditions. no predefined schedule of visits or medical procedures are required. data are collected on a semi-annual basis by physicians documenting assessment of disease severity, medication use, and adverse events. upon enrollment, patients complete a health assessment questionnaire. as this is an observational study, no study drugs are administered. through the course of the registry, analyses will be performed to support submissions to health authorities, and questions of academic interest.

Eligibility criteria:
inclusion criteria: * patients must be diagnosed with crohn's disease exclusion criteria: * patients participating in clinical trials for crohn's disease or other conditions also were not eligible to be enrolled in the treat™ registry * patients who are unable to participate in the program for 2 years or more.

Keywords: infliximab immune disorder remicade registry crohn's disease
coronary microcirculatory and bioresorbable vascular scaffolds

Conditions: CHD - Coronary Heart Disease; Angina, Stable; Myocardial Ischemia

Summary: angina and heart attacks are caused by narrowings in the coronary arteries (blood vessels) supplying the heart. these narrowings can be opened using a balloon and stent (angioplasty). traditionally, stents are constructed from metal and are permanent. however, newer stents are being constructed from carbohydrate polymers (scaffolds), which allow them to reabsorb over time leaving no permanent implant. new data has suggested that these scaffolds appear to reduce recurrent angina and may alter the blood flow down the artery. however, it is not known whether this is due to the scaffolds themselves or the way the scaffolds are inserted. in this study we hope to measure the blood flow to the heart and assess changes in that flow during stent and scaffold insertion. it is also important to know whether these effects are durable and thus, a cohort of patients will return at 3-months to be restudied. these data are important to help us understand why blood flow is affected by stent/scaffold selection or device implantation technique and whether this results in better long-term outcomes.


Eligibility criteria:
inclusion criteria: 1. patient age \>18 years, \<75 years. 2. lesion suitability for bvs deployment: target vessel calibre \>2.3mm and \<3.8mm reference diameter, without significant tortuosity or calcification. 3. listed for single-vessel pci procedure. 4. lesion length≤28mm (to accommodate single bvs/des) 5. preserved left ventricular ejection fraction (ef≥50%). exclusion criteria: 1. patients with confirmed myocardial infarction within the preceding 2 months. 2. allergy or intolerance to aspirin, clopidogrel, prasugrel or ticagrelor or contraindication to 12 months' dual antiplatelet therapy. 3. contraindication to use of adenosine (asthma/chronic lung disease with documented bronchoreactivity). 4. significant known comorbidity or terminal condition with life expectancy \<6 months. 5. pregnancy. 6. coagulopathy or warfarin treatment. 7. significant renal impairment (baseline creatinine\>130 mmol/l). 8. other comorbid condition that may affect microcirculatory function or troponin release (eg. seropositive inflammatory conditions). 9. inability to comply with follow-up requirements. 10. target lesion in left mainstem, saphenous vein or arterial grafts. 11. chronic total occlusion.

Keywords: coronary stent pci bvs index of microcirculatory resistance
effect of ppci on diastolic function & levels of galactin-3 in patients with stemi

Conditions: STEMI - ST Elevation Myocardial Infarction

Summary: * 2d echocardiography with color doppler assessment: it will be done within 24 h after ppci * peripheral blood samples were obtained within 48 hours after acute mi, and the serum will be frozen at -70°c until tested for galactin-3 level. * follow up 2d doppler echocardiography: will be repeated at 40 days of the event.

2d echocardiography with color doppler assessment: it will be done within 24 h after ppci. measurements will be as following: 1. pulsed wave (pw) doppler will be performed in the apical 4chamber view within a 3 mm sample volume at the tip of the mitral leaflets to obtain mitral inflow velocities to assess lv filling. 2. e (early diastolic)/a (late diastolic) - using pw doppler, the peak e and a velocities were recorded, then the ratio of e/a will be calculated. 3. ivrt (isovolumic relaxation time) - derived by placing the cursor of continuous wave (cw) doppler in the lv outflow tract to simultaneously display the end of aortic ejection and the onset of mitral inflow. 4. deceleration time (dt) - from the peak of e wave to baseline. 5. e/e'- pw tissue doppler imaging (tdi) was performed in the apical views to acquire mitral annular velocities. the sample volume will be positioned at or 1 cm within the mitral leaflet's septal and lateral insertion sites. 6. left atrial volume and left atrial volume index (lavi) - the maximal left atrial (la) volume measured from the apical four-chamber view using the modified simpson method in end-systole before mitral valve opening. the lavi obtained for all patients by dividing the la volume by the body surface area. biochemical measurements: peripheral blood samples were obtained within 48 hours after acute mi, and the serum will be frozen at -70°c until tested for galactin-3 level. follow up 2d doppler echocardiography: all previous echocardiographic measurements will be repeated at 40 days of the event.

Eligibility criteria:
inclusion criteria: * all patients of sample size admitted to the cardiology department of assiut university hospital with: 1. acute typical chest pain 2. positive cardiac enzymes. 3. ecg shows st-segment elevation mi 4. documented occlusion of ca then treatment by ppci exclusion criteria: * 1. patients with well-known factors of left ventricular diastolic dysfunctions, including high blood pressure (over 140/90 mmhg), hypertrophic cardiomyopathy, left ventricular hypertrophy, bundle branch block, ventricular fibrillation, ventricular arrhythmia, severe valvular disease, complete heart block, and previous cabg. 2. patients with the end-stage renal disease usually have markedly increased galactin-3 levels 3. prior use of thrombolytic agents 4. refusal of ppci due to social or religious concerns 5. st elevation on ecg without obvious coronary artery diseases such as acute myocarditis, early repolarization, or takotsubo cardiomyopathy 6. atrial fibrillation at the time of echocardiography examination.
use of chewing gum to facilitate appetite control and weight loss

Conditions: Overweight; Obesity

Summary: this purpose of this study was to test the use of chewing gum as an adjunct to lifestyle modification to facilitate appetite control and weight loss in overweight and obese individuals.


Eligibility criteria:
inclusion criteria: * 21-75 years of age * body mass index of 25-45 inclusive exclusion criteria: * major medical psychiatric conditions * medications know to effect weight * full or partial dentures * 18 or fewer teeth * regular gum chewing (≥ 2 pieces/day) * use of any tobacco product * sensitivity to the following ingredients (mint, magnolia bark, eggs, or english muffins) * history of pku * sensitivity or allergy to aspartame * current/history of alcohol abuse or addiction (within 5 year) * recreational drug use * recent significant weight change (+/- 5% in previous 6 months) * currently pregnant or nursing and willingness not to get pregnant during course of study * participation in any other research studies * proximity to clinic (within one hour) * access to reliable transportation
predictive factors of mortality in invasive fungal disease in post-surgical critical care unit

Conditions: Fungal Invasive Disease

Summary: invasive fungal disease in the critically ill patient is a serious complication that increases hospitalization times, morbidity and mortality, and healthcare costs. our team proposes a retrospective observational study of patients from the resuscitation unit of the hospital la fe who during the years 2016-2019 presented invasive candidiasis. the investigators intend to detect if there are possible specific risk factors that favor the development of invasive candidiasis in colonized patients and if these associated risk factors could be considered as 'triggers' or alerts for the implementation of specific care in these patients. to do this, the investigators intend to study the blood samples taken from patients, taking into account different types of perioperative variables from them, which will be statistically analyzed, so that evidence-based inferences can be drawn to demonstrate our hypothesis.

the hypothesis is that there are factors predisposing to the development of invasive fungal disease, invasive candidiasis, and that the detection of these factors may allow detecting the population at risk and implementing both pharmacological measures and general strategies to reduce the mortality of fungal infection. primary objective: to determine if candida auris is associated with increased risk of mortality in invasive fungal disease and the risk factors for mortality in the invasive fungal disease, including the species of candida that causes this disease. secondary objectives: determination of predictors of mortality in invasive fungal disease. prepare and validate a score in our environment that allows discriminating those patients with a high risk of mortality. to analyze the pharmacological management that has been carried out in patients who develop candidemia due to auris. detect hospital stays of both population groups, in terms of health management. type of study: observational, longitudinal, and retrospective study of cases and controls of a selected exposed population that developed the disease over time or not.

Eligibility criteria:
inclusion criteria: * more than 18 years * admitted to the icu that present fungal invasive disease
delayed cord clamping in premature infants

Conditions: Hypothermia; Anemia

Summary: delayed cord clamping has been shown to decrease the risk of bleeding in the brain of premature infants. however this procedure is not standard due to concerns that the premature infant will get too cold. in this study the investigators look at using a plastic covering and a chemical warmer to keep the small premature baby warm while waiting 30-60 seconds to clamp the umbilical cord.

enrolled premature infants will be compared to age matched historical controls that did not receive delayed cord clamping but were placed under a warmer immediately after birth. outcomes to be analyzed include initial body temperature, hematocrit at birth and 24 hours of age, number of red blood cell transfusions during hospital stay, umbilical cord gas, first blood gas following delivery, blood pressure data in the first 24 hours, fluid bolus and inotrope requirement in the first 24 hours, incidence of intraventricular hemorrhage and late-onset sepsis, peak bilirubin level, length of phototherapy, and apgar scores.

Eligibility criteria:
inclusion criteria: * premature infants at 24-28 completed weeks gestation at the time of delivery * informed consent obtained from parents prior to delivery exclusion criteria: * multiple gestation (twins, triplets, etc) * prolonged fetal bradycardia * placental abruption or previa * maternal illness * major congenital anomalies * maternal fever in labor * fetal illness (e.g. isoimmune hemolysis)

Keywords: delayed cord clamping premature infants hypothermia anemia intraventricular hemorrhage anemia in premature infants
postoperative catheterization after anterior colporrhaphy

Conditions: Cystocele; Cystitis

Summary: randomised controled multicenter trial about the appropriate length of postoperative catheterization after anterior colporrhaphy. patients are included at the moment that they are planned for surgery and are allocated to one of the study arms after the operation in the recovery by a digital randomisation-procedure. 230 patients will be enrolled in the study and half of the patients will have a catheter during five days postoperatively and the other half will be catheterized only during two days. main outcome measurements regards replacement of a catheter because of bladder retention and the occurence of cystitis.


Eligibility criteria:
inclusion criteria: * all patients planned for a cystocele repair exclusion criteria: * patients who already have voiding problems before the operation not related to the cystocele * patients that are not capable of understanding our patient information form because of mental status or language

Keywords: postoperative catheterization colporrhaphy cystocele cystitis
survivorship post-hct optimization program

Conditions: Hematologic Malignancy

Summary: the purpose of this project is to investigate the effects of 12 weeks of high-intensity interval training (hiit) and resistance training on several domains of health including physical function, cognitive function, mental health, and quality of life in patients who have undergone hematopoietic stem cell transplant (hct). in addition, the project will determine the effects of 12 weeks of hiit and resistance training on physical function, caregiver strain, mental health, and caregiver confidence in individuals who are providing care for patients undergoing hct.


Eligibility criteria:
patient inclusion criteria: 1. ≥18 years old 2. english speaking 3. within 90 ± 30 days post allogenic hct caregiver inclusion criteria: 1. ≥18 years old 2. english speaking 3. providing post-discharge care for the patient who has undergone hct patient and caregiver exclusion criteria: 1. have an absolute contraindication to exercise including a recent acute cardiac event (\<6 months), unstable angina, uncontrolled dysthymias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspects or known dissecting aneurism, or coronary artery disease. 2. in addition to these absolute contraindications, the patient and caregiver will complete cardiopulmonary exercise testing (cpet) where the heart rate and heart rhythm will be monitored via a 12-lead ecg before, during, and after the test. the results from the cpet will be reviewed by a physician before the subject is cleared to participate in the hiit and resistance training program. if the participant is not cleared by the physician following the cpet, then the patient and his or her caregiver will not be eligible to participate in the study.
a safety and morab-028 dose determination study in subjects with metastatic melanoma

Conditions: Metastatic Melanoma; Malignant Metastatic Melanoma; Advanced Melanoma; Melanoma

Summary: the purpose of this study is to evaluate whether therapy with morab-028 is safe, effective, and to determine the appropriate dose of morab-028 in the treatment of metastatic melanoma.

melanoma is a serious form of skin cancer. if untreated, the melanoma can spread beyond the original affected tissue and invade distant tissue and organs. treatment for metastatic melanoma includes medical treatments (chemotherapy or immunotherapy), surgery, or radiation therapy. morab-028 is a recombinant human immunoglobulin m (igm) monoclonal antibody that recognizes a cell surface diacyl ganglioside named disialoganglioside (gd2). gd2 is overexpressed in tumors of neuro-ectodermal origin such as melanomas, neuroblastomas, small-cell lung carcinomas, and many sarcomas, while absent in most normal tissues. gd2 expression has been demonstrated in human melanoma and small cell lung cancer by thin layer chromatography and radiolabeled anti-gd2 antibody detection. it is hypothesized that one mode of action of morab-028 is complement-dependent cytotoxicity. complement-dependent cytotoxicity is a mechanism for killing tumor cells in which an antibody bound to the target cell surface fixes complement, which results in assembly of the complement membrane attack complex that punches holes in the target cell membrane resulting in subsequent cell lysis. igms strongly bind to c1q and robustly activate complement-dependent cytotoxicity. morab-028 is being developed as a potential therapy for gd2-positive tumors.

Eligibility criteria:
inclusion criteria: * measurable metastatic melanoma that has failed standard therapy * males and females greater than or equal to 18 years of age * life expectancy of greater than or equal to 3 months exclusion criteria: * significant cardiovascular impairment * clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results * chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to morab-028
a cross-sectional study for the determination of the prevalence of non-valvular atrial fibrillation among patients diagnosed with hypertension

Conditions: Hypertension; Atrial Fibrillation

Summary: arterial hypertension has been recognized as a major causal factor for atrial fibrillation (af), the most common sustained cardiac arrhythmia. in light of its worldwide increasing prevalence and incidence and the accompanied increase in the risk of stroke, thromboembolic events and mortality, af has emerged as a global healthcare problem. early diagnosis of af, prior to the occurrence of complications is a recognized priority for the prevention of strokes. once diagnosed, anticoagulant therapy is the cornerstone in the management of the risk of stroke in af patients. the 2012 esc guidelines recommend the use of a risk factor-based approach to stroke risk stratification for af patients. this study aims towards gaining real-world data on the prevalence of non-valvular atrial fibrillation (nvaf) among hypertensives in greece. the rate of esc guideline-adherent antithrombotic therapy on the basis of stroke and bleeding risk assessments, and factors influencing treatment decision-making will be assessed as well in patients diagnosed with the arrhythmia. finally, potential differences in the nvaf prevalence in adequately and inadequately controlled hypertensives will be documented.


Eligibility criteria:
inclusion criteria: * female and male outpatients aged 60 years and older * patients having being diagnosed with arterial hypertension * for patients without a history of af diagnosis, the decision to perform electrocardiography testing, either standard 12-lead ecg or ambulatory ecg, at the study visit has been made as per the investigator's routine practice * patients with available medical records * written signed and dated informed consent exclusion criteria * presence of any condition/circumstance which in the opinion of the investigator would make the patient unfit to participate in the study or would compromise the quality of the study data (e.g., non-native speaker or patient who does not understand the local language unless reliable interpreter services are available; failure to cooperate due to major psychiatric disturbances, dementia, or substance use disorder) * patients currently participating in any investigational program with interventions outside of routine clinical practice or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment

Keywords: stroke prevention risk assessment
bf2.649 in patients with osa and treated by cpap but still complaining of eds

Conditions: Obstructive Sleep Apnea; Excessive Daytime Sleepiness

Summary: multicenter randomized double blind study versus placebo during 12 weeks with at first, an escalating dose period followed by stable dose period at the selected dose. this double-blind period can be followed by a 9 months open-label period if the patient wishes to continue with the study product.

the first period (12 weeks double blind period) will aim at demonstrating the efficacy and safety of bf2.649 by verifying whether the results of bf2.649 are superior to those of placebo. the aim of the second period (open label extension phase) will be to assess the long-term tolerance, as well as the maintenance of the bf2.649 efficacy.

Eligibility criteria:
inclusion criteria: * patients with osa treated by ncpap but still complaining with eds * ess score \> or = 12 exclusion criteria: * patient suffering from insomnia without osa * co-existing narcolepsy * patient with sleep debt not due to osa * acute or chronic severe disease

Keywords: sleep disorder obstructive sleep apnea excessive daytime sleepiness patients with osa treated by cpap presenting eds